Bone morphogenetic protein 4 is involved in cadmium-associated bone damage

Area of Science:

• Environmental toxicology
• Cell biology
• Biochemistry

Background:

• Cadmium (Cd) is a known bone toxicant that inhibits osteogenic differentiation.
• The bone morphogenetic protein (BMP)/SMAD signaling pathway regulates osteogenic differentiation, but its interaction with cadmium toxicity is unclear.
• Understanding this interaction is crucial for identifying biomarkers and therapeutic strategies for cadmium-induced bone damage.

Purpose of the Study:

• To investigate how cadmium affects BMPs and SMADs in human bone marrow mesenchymal stem cells (hBMSCs).
• To determine if BMPs can serve as biomarkers for cadmium-associated bone damage.
• To explore the therapeutic potential of BMPs in mitigating cadmium-induced bone toxicity.

Main Methods:

• In vitro exposure of hBMSCs to cadmium chloride (CdCl2) to assess BMP and SMAD expression.
• In vivo study of 134 subjects to correlate BMP levels with cadmium-associated bone damage.
• Mediation analysis to quantify the role of BMP-4 in the association between cadmium exposure and bone damage risk.

Main Results:

• Cadmium exposure promoted adipogenic differentiation and inhibited osteogenic differentiation in hBMSCs.
• Cadmium reduced the expression of BMP-2/4, SMAD4, and the p-SMAD1/5/9 complex.
• BMP-4 was found to mediate 39.32% of the association between cadmium exposure and bone damage risk.
• BMP-4 enhanced mineralization during differentiation in vitro.

Conclusions:

• Cadmium-induced bone damage is linked to the inhibition of the BMP/SMAD signaling pathway.
• BMP-4 plays a significant role in mediating cadmium's detrimental effects on bone.
• BMP-4 is a promising diagnostic biomarker and potential therapeutic target for cadmium-associated osteoporosis.